|
News & Events
Sagent Completes $30 Million Series A Financing Extension
Thursday, 04 September 2008
SCHAUMBURG, IL - Sagent Pharmaceuticals, Inc., a privately-held specialty
pharmaceutical company today announced the closing of a $30 million
extension of last year’s $53 million Series A financing, led by Vivo
Ventures. Proceeds from the financing will be used to fund near-term
product launches, product development activities and strategic business
initiatives.
“This additional financing round will allow us to advance additional
products to market and to avail ourselves of compelling, recently
discovered product acquisition opportunities,” said Jeffrey M. Yordon,
CEO, founder and chairman of the board of Sagent Pharmaceuticals. “We
appreciate the continued commitment our investors have demonstrated to
Sagent through this financing."
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, founded in 2006, is a privately held specialty
pharmaceutical company focused on developing, manufacturing, sourcing
and marketing pharmaceutical products, with a specific emphasis on
injectable products. Sagent has created a unique, global network of
resources, comprised of rapid development capabilities, sophisticated
manufacturing and innovative drug-delivery technologies, quickly
yielding an extensive portfolio of pharmaceutical products that fulfills
the evolving needs of patients. Sagent currently has more than 200
products in development.
To Discover Injectables Excellence™ and learn more about Sagent, please
visit www.sagentpharma.com.
About Vivo Ventures
Vivo Ventures is a life-sciences focused venture capital firm with more
than $650 million under management. Vivo Ventures is currently making
investments from its sixth fund of $275 million into promising
biotechnology and life science companies.
With more than 90 years of scientific and operational expertise in
biotechnology, Vivo helps its portfolio companies develop corporate
strategy, arrange licensing agreements and strategic alliances, recruit
key management personnel and acquire new products and technology to
accelerate growth. Its current portfolio includes more than 60 private
and public biotechnology companies in the areas of biopharmaceuticals,
specialty pharmaceuticals and medical devices.
|
